Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Researchers Unearth New Clues About How Prostate Cancer Evolved

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
With the help of a computational model, Broad researchers were able to reconstruct the genomes of prostate cancer cells.

Imagine you’re visiting the Acropolis. You tour the ruins, taking snapshots as you go. Later, at home, you tell your family and friends about your visit and someone, noticing the building’s advanced deterioration, asks: well, how did it get that way? Now, say you knew nothing about the Acropolis, and could only rely on your photos and memory to describe the place. What would you say? Without the rich archeological history of the Acropolis, you’d be missing a huge part of the story.

Now imagine a cancer cell as a similar kind of ruin. Over time mutations accumulate, pushing the cell further and further from its original shape and function, eventually overwhelming its ability to control growth. When scientists sequence a cancer genome, the resulting data is essentially a snapshot of the tumor and its mutations at the time it was sampled. But what stories would emerge if we knew the order in which those mutations occurred?

In the case of prostate cancer — the second most lethal cancer in American men — research has demonstrated that structural genomic alterations, such as broken and rearranged chromosomes, are key to tumor development and progression. With no evidence to suggest a chronology for these breaks and repairs, researchers generally assumed that they accumulated gradually over time, often as a result of cell division. But new research is suggesting the deterioration isn’t gradual at all.

For the first time, a team of scientists from the Broad, Dana-Farber Cancer Institute, and Weill Cornell Medical Center has revealed the “cellular archeology” of prostate cancer cells. Using a computational model, the team was able to track how mutations accumulated in the genomes of 55 prostate cancer tumors. The results of the study, recently published in Cell, revealed that mutations often occur in abrupt, interconnected bursts, resulting in large-scale rearrangement of DNA.

“We’ve known for a long time that the rearrangement of certain chromosomes is key to the development of prostate cancer and we suspected they were the result of some very complex DNA-damaging events,” says Sylvan Baca, the study’s first author and cellular Indiana Jones. As a researcher in Broad senior associate member Levi Garraway’s lab and part of the Broad/Dana-Farber/Weill Cornell team, Baca had observed how the genomes of prostate cancer cells appeared as if they’d been taken apart and put back together the wrong way. In an attempt to fill in the gaps in the story, Baca developed ChainFinder — a modeling algorithm that was able to reconstruct the shattered genomes and determine the chronology of the alterations.

“Interestingly, our findings indicate that many of these rearrangements arise in a highly interdependent fashion, and may often occur together within a single cell,” said Baca, who along with the other members of the team, dubbed these damaging events “chromoplexy” from the Greek word to interweave or integrate. Similar to the idea of punctuated evolution in the population sciences — which suggests that that major genetic changes can happen to select populations in a relatively small window of time — chromoplexy indicates that sets of mutations may originate together, drastically altering cells.

“While we can’t yet say much about the timing of the events, or what the events are, the study suggests that just a few of these events may be enough to lead to the changes we know result in prostate cancer,” says Baca. A major goal of prostate cancer research is to identify new drug targets, as well as genetic characteristics that could distinguish aggressive forms of the disease. While researchers are currently working to further understand the initiating source of these events, Baca speculates that in the future profiling cells for chromoplexy may be a way to identify certain “linchpin” mutations in particular cancers.

The idea that periodic bursts of genetic upheaval, resulting in a cascade of changes eventually leading to tumor growth, has been hinted at in other cancers — but the identification of chromoplexy suggests this sort of genomic derangement may be far more common than previously thought.

“The complex genomic restructuring we discovered is a unique and important model of carcinogenesis which likely has relevance for other tumor types,” said Garraway, a co-senior author of the study. The team is now using ChainFinder to study other cancers known for containing complex genetic rearrangements, including lung adenocarcinoma, melanoma, and breast cancer, to see if those changes are also the result of chromoplexy.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Broad Institute & Google Genomics Combine Bioinformatics and Computing Expertise
Both companies explore how to break down major technical barriers that increasingly hinder biomedical research.
Thursday, June 25, 2015
CRISP-Disp Leverages CRISPR-Cas9 to Deliver RNA Structures to Targets in the Genome
A team of researchers from the Broad Institute and the Harvard Stem Cell Institute has developed CRISP-Disp, a method that expands on the CRISPR-Cas9 system, allowing researchers to display multiple, large RNA structures on the Cas9 protein.
Wednesday, June 10, 2015
GTEx: Useful Expression For Cancer Research
GTEx Project has recently published several papers reporting on findings from its two-year pilot phase.
Tuesday, May 26, 2015
Single-cell Analysis Hits its Stride
Advances in technology and computational analysis enable scale and affordability, paving the way for translational studies.
Saturday, May 23, 2015
Highly Efficient New Cas9 for In Vivo Genome Editing
New finding is expected to expand therapeutic and experimental applications of CRISPR.
Tuesday, April 07, 2015
Broad Institute of MIT and Harvard and Bayer Healthcare Expand their Partnership
Collaboration to develop therapies for cardiovascular disease.
Thursday, April 02, 2015
In vivo CRISPR-Cas9 Screen Sheds Light On Cancer Metastasis And Tumor Evolution
Genome-scale study points to drivers of tumor evolution and metastasis, provides roadmap for future in vivo Cas9 screens.
Friday, March 06, 2015
Scientists Map the Human Loop-ome, Revealing a New Form of Genetic Regulation
Researchers describe the results of a five-year effort to map, in unprecedented detail, how the 2-meter long human genome folds inside the nucleus of a cell.
Tuesday, December 23, 2014
Disorder in Gene-Control System is a Defining Characteristic of Cancer, Study Finds
Findings indicate that the disarray in the on-off mechanism is one of the defining characteristics of cancer.
Tuesday, December 23, 2014
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
Thursday, November 27, 2014
Dramatic Response And Resistance To Cancer Drug Traced
Sequencing reveals why thyroid tumor responded to, and eventually resisted, treatment.
Friday, October 10, 2014
Study Expands the Cancer Genomics Universe
The universe of cancer mutations is much bigger than previously thought, and key cancer genes are still to be discovered.
Tuesday, January 28, 2014
Predicting Cancer’s Next Move
Research offers a new approach to studying drug resistance in cancer.
Monday, November 11, 2013
Mexico-US Genomics Partnership Launches Second Phase
SIGMA 2 is aimed at harnessing genomic medicine for the benefit of Latin America and the world.
Wednesday, October 30, 2013
Understanding Triglycerides’ Role in Coronary Disease
The study leverages new genetic data from a related genome-wide association study, suggests that lowering triglyceride levels through treatment may help reduce the risk of coronary heart disease.
Wednesday, October 09, 2013
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!